Global Artificial Intelligence in Drug Optimization & Repurposing Market is estimated to be worth USD 450.33 Million in 2022 and is projected to reach a value of USD 7,874.43 Million by 2030, growing at a CAGR of 43% during the forecast period 2023-2030.
The Drug Discovery Process consists of several phases and sets of actions. Early Drug Discovery, Pre-Clinical Phase, Clinical Phases, and Regulatory Approval are the four major phases. The fundamental purpose of the lead optimisation phase, as the final stage in the preclinical drug development process, is to preserve the desirable qualities of the drug's key components while decreasing any inadequacies in its structure. The process of discovering new therapeutic uses for old/existing/available medications is known as drug repurposing (DR). It is a successful technique for identifying or creating novel pharmacological or therapeutic indications for medicinal compounds. AI technology is applied at every stage of the medication discovery process, which eliminates the health risks associated with preclinical studies while also significantly lowering the cost. Researchers may use AI to simplify the medication delivery process, thereby saving time and improving the efficacy and safety of pharmacological therapy. This can lead to more focused and successful medicines that are personalised to individual patients' genetic, metabolic, and clinical profiles. Based on massive pharmaceutical data and the machine learning process, AI is an excellent data mining tool. Artificial intelligence technologies combined with process performance and capability measurements may be used to proactively monitor manufacturing processes for trends. AI techniques combined with big data are projected to significantly increase the efficacy of medication repurposing and the discovery of novel treatments for a variety of complicated human diseases such as COVID-19, malignancies, Alzheimer's disease, and others.
Global Artificial Intelligence in Drug Optimization & Repurposing Market Drivers:
Increasing Adoption has significantly boosted the growth of AI.
Data science and artificial intelligence (AI) are becoming increasingly crucial in medication research and development. In addition to developing novel treatments, AI accelerates the work of current drug development and clinical teams, allowing them to make more informed and precise research decisions. In small-molecule drug development, AI may add value in four ways: access to new biology, enhanced or novel chemistry, higher success rates, and faster and cheaper discovery methods. Furthermore, Artificial intelligence can assist researchers in analysing enormous datasets and identifying patterns that would be difficult or impossible to find using traditional approaches. This can lead to more effective therapies. A lot of R&D activities are being provided to develop computational tools to further understand the diseases and develop effective drugs against the same.
The surge in the number of cases of chronic disease has delved into the prospects of AI.
According to WHO, if the current trend continues, chronic diseases such as cardiovascular disease, cancer, diabetes, and respiratory illnesses will account for 86% of the 90 million deaths each year by 2050, representing a staggering 90% increase in absolute numbers since 2019. AI can swiftly grasp how cancer cells gain resistance to anticancer treatments, which can aid in drug development and therapeutic use. AI increases tumour neoantigen detection and tumour immunotherapy effectiveness. Based on clinical data, chest imaging, lung pathology, and pulmonary function tests, AI can assist in establishing diagnosis and predicting outcomes in pulmonary disorders. AI platforms provide valuable insights for drug discovery and minimizing the severity of diseases. Therefore, these factors are projected to enhance and discover more knowledge thereby having a lot of scope in the coming period.
Global Artificial Intelligence in Drug Optimization & Repurposing Market Challenges:
The advanced tools used and being developed require substantial amounts of investments which can be the biggest hindrance in the healthcare industry. To produce accurate predictions and choices, AI systems rely on high-quality data. However, data used in medication development is frequently insufficient, inconsistent, or biased. This can result in erroneous or unreliable AI algorithm outputs, which might stymie the medication development process. Furthermore, during clinical trials, only a few molecules can be successful in providing accurate data which can bleed the sector dry.
Global Artificial Intelligence in Drug Optimization & Repurposing Market Opportunities:
Opportunities are being provided in the R&D sector through collaborations, investments, and schemes. The research field has enormous amounts of publications, journals, and books for a better understanding which combines the areas of computer science, machine learning and an understanding of drug development. A lot of pharmaceutical and IT companies are working to further explore the understanding by employing bioinformatics tools to get a better understanding of the abnormalities present in the sequences. All these initiatives have caused a remarkable change helping in generating an exponential curve in the industry.
COVID-19 Impact on the Global Artificial Intelligence in Drug Optimization & Repurposing Market:
Despite the economic slowdown during the pandemic, the AI field turned out to be beneficial. Skilled professionals and Research Scientists were hired to detect patterns and for vaccine development. One of the objectives and responsibilities of AI in vaccine development was to study the proteins that comprised the virus, such as the spike protein(s). An AI system could sift through hundreds of components in a complex structure to select the ones that were most likely to evoke a significant immune response. With the increased use of AI in the healthcare industry, it was possible to anticipate early COVID-19 signs and thereby restrict the spread of the virus. It was used to screen and follow patients, as well as anticipate future illnesses, by employing algorithms that analyse data to uncover meaningful trends.
Global Artificial Intelligence in Drug Optimization & Repurposing Market Recent Developments:
In May 2023, Google Cloud launched two A.I.-powered tools to accelerate drug discovery and precision medicine. Target and Lead Identification Suite, is designed to help companies predict and understand the structure of proteins, a fundamental part of drug development. Multiomics Suite will help researchers ingest, store, analyse and share mass amounts of genomic data.
In July 2021, an AI system by DeepMind called AlphaFold predicted the protein structures for 330,000 proteins, including all 20,000 proteins in the human genome.
In January 2021, BenevolentAI announced that AstraZeneca had selected the first AI-generated drug target from their 2019 collaboration – a novel chronic kidney disease (CKD) target.
During the second half of 2020, Pfizer, invested $120 million in biotechnology innovation through the Pfizer Breakthrough Growth Initiative and effectively used AI to conduct COVID-19 vaccine and streamline distribution. The company drew on digital technologies and AI to roll out its vaccine to market in less than a year.
Exscientia revealed the first-ever AI-designed medicinal molecule to start human clinical trials in early 2020.
ARTIFICIAL INTELLIGENCE IN DRUG OPTIMIZATION & REPURPOSING MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2022 - 2030 |
|
Base Year |
2022 |
|
Forecast Period |
2023 - 2030 |
|
CAGR |
43% |
|
Segments Covered |
By Therapeutic Area, Technology, Offering, End-Users, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
Microsoft, IBM, Exscientia, GNS Healthcare, Alphabet, Benevolent AI, Cloud Pharmaceuticals, NVIDIA Corporation, DEEP GENOMICS, Cyclica |
Oncology
Neurodegenerative Diseases
Cardiovascular Disease
Genetic Diseases
Metabolic Diseases
Infectious Disease
Others
Oncology is the largest growing in the Global Artificial Intelligence in Drug Optimization & Repurposing Market. This is because many malignancies are predicted and automated using artificial intelligence (AI), which has emerged as a viable tool for enhancing healthcare accuracy and patient outcomes. Deep knowledge-based AI applications in cancer include risk assessment, early diagnosis, patient prognosis estimate, and therapy selection thereby increasing life expectancy. The infectious disease segment is the fastest growing owing to factors like helping with early detection, optimising pharmaceutical and non-pharmaceutical therapeutic tactics, prediction models, understanding infection mechanisms, telemedicine, vaccine development, etc.
Machine Learning
Deep Learning
Support Vector Machine (SVM)
DeepPurpose 20
Natural Language Processing
Virtual Screening
Others
Machine Learning is the largest growing in the Global Artificial Intelligence in Drug Optimization & Repurposing Market. Machine learning approaches enhance decision-making in pharmaceutical data across a wide range of applications, including QSAR analysis, hit discovery, and de novo drug designs, to produce more accurate results. Deep Learning, a subset of Machine Learning is the fastest-growing segment in the Global Artificial Intelligence in Drug Optimization & Repurposing Market. SVM is widely used for drug optimization. The capacity of SVMs to categorise active or inactive molecules has allowed substances to be prioritised for virtual screening. DeepPurpose [20] is majorly used for drug repurposing because it helps in drug–target interaction (DTI) integrating encoding-based approaches of drug molecules and protein amino acid sequences.
Services
Softwares
The service sector is the largest growing in the Global Artificial Intelligence in Drug Optimization & Repurposing Market owing to the demand, time taken, and accuracy associated with the same. The service sector is the fastest-growing sector in the coming years.
Biotechnology firms and Pharmaceutical Companies
Research Organizations
Academic Institutes
Others
Biotechnology firms and Pharmaceutical Companies are the largest growing in the Global Artificial Intelligence in Drug Optimization & Repurposing Market. This is mainly because of better funding, opportunities, collaborations, advanced technologies and databases. However, research organizations are the fastest growing because of schemes, initiatives and grants being provided by Government bodies.
North America
Europe
Asia-Pacific
South America
Middle East & Africa
North America dominates the Global Artificial Intelligence in Drug Optimization & Repurposing Market owing to huge investments, economy, advanced research, increasing adoption, collaborations and partnerships. USA and Canada are the top leading countries. Asia Pacific is the fastest growing because of changes in regulations, grants, funding, and research activities regarding the concept of personalised medicine. China is a Tier 1 country with the most AI centres and is undergoing national digitization in the healthcare industry.
Global Artificial Intelligence in Drug Optimization & Repurposing Market Key Players:
Microsoft
IBM
Exscientia
GNS Healthcare
Alphabet
Benevolent AI
Cloud Pharmaceuticals
NVIDIA Corporation
DEEP GENOMICS
Cyclica
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
Global Artificial Intelligence in Drug Optimization & Repurposing Market is estimated to be worth USD 450.33 Million in 2022 and is projected to reach a value of USD 7,874.43 Million by 2030, growing at a CAGR of 43% during the forecast period 2023-2030.
AnThe Global Artificial Intelligence in Drug Optimization & Repurposing Market Drivers is the increasing adoption of AI and a surge in the number of chronic disease cases.
Based on the End-Users, the Global Artificial Intelligence in Drug Optimization & Repurposing Market is segmented into Biotechnology firms and Pharmaceutical Companies, Research Organizations, Academic Institutes, and Others.
The United States is the most dominating country in the region of North America for the Global Artificial Intelligence in Drug Optimization & Repurposing Market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
